ANSWER: B

Rationale:

This vignette illustrates the intersection of two pharmacokinetic principles that make phenytoin one of the highest-risk drugs for CYP inhibitor interactions. First, phenytoin is metabolized primarily by CYP2C9 (and to a lesser extent CYP2C19) to its inactive metabolite HPPH. Fluconazole is a potent inhibitor of both CYP2C9 and CYP2C19. Second, phenytoin at therapeutic plasma concentrations (10–20 mg/L) already operates near the saturation point of its metabolizing enzymes — it exhibits Michaelis-Menten (zero-order) kinetics in the therapeutic range. The consequence of this combination is particularly dangerous: any inhibition of the already near-saturated CYP2C9 pathway produces a disproportionate and non-linear rise in phenytoin plasma concentration. In this patient, phenytoin levels rose from a presumed therapeutic level to 38 mg/L — nearly double the upper limit — producing the classic triad of cerebellar toxicity (nystagmus, diplopia, ataxia). Management requires immediate phenytoin dose reduction, close monitoring, and careful dose re-titration after fluconazole is discontinued. Option A is incorrect — fluconazole is a CYP inhibitor, not an inducer; and HPPH is an inactive metabolite. Option C is incorrect — protein binding displacement is not the primary mechanism; fluconazole does not significantly displace phenytoin from albumin, and even if it did, displacement alone without metabolic inhibition produces a transient and self-limiting effect. Option D is incorrect — phenytoin is not significantly renally excreted; it undergoes hepatic hydroxylation followed by glucuronidation, with renal excretion of metabolites rather than parent drug. Option E is incorrect — fluconazole inhibits, not induces, P-glycoprotein; and P-gp at the BBB typically limits CNS drug entry rather than promoting it.

ANSWER: B

Rationale:

Rifampicin is the most potent clinical inducer of drug-metabolizing enzymes in common use. It activates the pregnane X receptor (PXR) and constitutive androstane receptor (CAR), transcriptionally upregulating CYP3A4, CYP2C9, CYP2C19, CYP2B6, and P-glycoprotein in the intestinal wall and liver. For combined oral contraceptives, CYP3A4 induction dramatically increases the first-pass and systemic metabolism of both ethinylestradiol and levonorgestrel, reducing their plasma concentrations — in some studies by 50–60% — to levels insufficient to maintain consistent hypothalamic-pituitary-ovarian axis suppression. Breakthrough bleeding is an early clinical sign of inadequate ovarian suppression and signals contraceptive failure. This interaction is well-documented and clinically critical: rifampicin renders standard-dose OCPs unreliable, and affected patients require alternative or additional contraception (e.g., barrier methods, depot medroxyprogesterone, copper IUD) for the duration of TB treatment and for at least four weeks after rifampicin is stopped, as enzyme induction persists for several weeks after discontinuation due to the time required for CYP enzyme turnover. Option A is incorrect — rifampicin is an inducer, not an inhibitor, of CYP3A4; inhibition would increase, not decrease, OCP hormone levels. Option C is incorrect — rifampicin does not displace estrogens from sex hormone-binding globulin; this is not a documented interaction mechanism. Option D is incorrect — rifampicin induces, not inhibits, P-glycoprotein, which would reduce intestinal absorption of P-gp substrates; this is the opposite of what is described, and even if it occurred as described, the pharmacodynamic feedback reasoning is incorrect. Option E is incorrect — rifampicin induces both Phase I (CYP) and Phase II (UGT, GST) enzymes simultaneously; the interaction is not limited to Phase II.

ANSWER: B

Rationale:

The pharmacokinetic justification for extended dosing intervals in CKD for renally eliminated drugs rests directly on the relationship between renal clearance, half-life, and accumulation. Elimination half-life (t½) = (0.693 × Vd) / CL. For vancomycin, which is eliminated almost entirely by glomerular filtration (renal clearance total clearance), a reduction in eGFR from normal (~120 mL/min) to 18 mL/min/1.73m² reduces total clearance by approximately 85%. Since Vd is largely unaffected by CKD (vancomycin Vd 0.4–1.0 L/kg, determined by tissue binding rather than renal function), the dramatic fall in clearance produces a proportionate prolongation of half-life — from approximately 4–8 hours in normal renal function to 70–100 hours or more in severe CKD. If standard dosing intervals (every 6–12 hours) are maintained, vancomycin accumulates progressively, with trough concentrations rising into the nephrotoxic and ototoxic range. Extended intervals (every 24–96 hours depending on eGFR) allow adequate time for plasma concentrations to fall between doses. TDM (measuring AUC24/MIC or trough concentrations) is essential because residual renal function varies widely between patients with the same nominal eGFR. Option A is incorrect — CKD does not systematically reduce Vd; Vd may actually increase slightly in advanced CKD due to fluid overload and altered protein binding, but this is not the primary justification for extended intervals. Option C is incorrect — vancomycin undergoes no meaningful hepatic metabolism; CYP activity is irrelevant to vancomycin dosing. Option D is incorrect — vancomycin is not orally bioavailable (it is administered intravenously or intramuscularly for systemic infections) and has no first-pass extraction. Option E is incorrect — vancomycin has relatively low plasma protein binding (~55%) and CKD-related changes in protein binding, while present, are not the primary pharmacokinetic basis for extended dosing intervals.

ANSWER: A

Rationale:

During normal pregnancy, cardiac output increases by 30–50%, renal blood flow increases by 50–80%, and GFR rises by approximately 50% above pre-pregnancy baseline by the second trimester — a physiological adaptation to accommodate increased metabolic demands and fetal waste clearance. For drugs eliminated primarily by renal mechanisms (glomerular filtration and/or tubular secretion), increased GFR accelerates plasma clearance, reducing systemic drug concentrations (relevant for drugs where systemic exposure drives efficacy or toxicity) while simultaneously increasing the rate of drug delivery into the urine. For nitrofurantoin, which exerts its antibacterial effect locally within the urinary tract, increased GFR and tubular secretion during pregnancy increase the amount of drug delivered to the urine per unit time — potentially maintaining or enhancing urinary antibacterial concentrations despite reduced plasma levels. This is an important pharmacokinetic principle: for urinary tract-acting drugs, pregnancy-related renal physiology may actually favor efficacy at the site of action even as systemic plasma concentrations fall. Option B is incorrect — increased GFR accelerates, not reduces, renal clearance; it does not promote tissue redistribution. Option C is incorrect — urinary pH in pregnancy does not undergo systematic alkalinization sufficient to ion-trap nitrofurantoin (pKa 7.2 means it is approximately 50% ionized at pH 7.2); and even if ion trapping occurred, it would reduce reabsorption and increase — not decrease — urinary drug concentrations. Option D is incorrect — tubular transporters are not saturated by increased renal blood flow; flow increases substrate delivery to transporters but does not saturate them under normal physiological conditions. Option E is incorrect — nitrofurantoin is not a CYP3A4 substrate; its metabolism is primarily by tissue reduction (not hepatic CYP oxidation), and progesterone does not significantly induce CYP3A4 at physiological pregnancy concentrations.